PharmTech Drug Digest 11.20
News|Articles|July 22, 2016

Curida to Manufacture PCI Biotech’s Amphinex

Curida will manufacture PCI Biotech’s Amphinex, a drug used to treat bile duct cancer.

On July 1, 2016, Curida and PCI Biotech entered into an agreement to manufacture Amphinex, PCI’s lead product candidate. Amphinex is undergoing international clinical trials for bile duct cancer, Curida said in a press announcement. Entering into partnerships with biotech companies at an early stage is part of Curida’s long-term growth strategy, Leif Rune Skymoen, CEO of Curida, noted in a press announcement. 

Curida is located in Elverum, Norway and offers contract manufacturing, development, and laboratory services, primarily for large and small companies in the pharmaceutical sector. Curida and PCI Biotech are co-located at the Oslo Cancer Cluster Incubator, which facilitates the research and development of new cancer treatments. 

Source: Curida

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.